Mar. 14 at 9:46 PM
Attached see
$SNDX valuation, analyst revenue estimates & related multiples compared to
$DAWN 's M&A exit valuation.
If DAWN's market cap (post M&A announcement) is now 1.03X DAWN 5-year analyst consensus, would SNDX command a higher 5-year multiple than 1.03X in a hypothetical M&A exit (excluding cash/debt) because;
1. SNDX revenues generated higher gross profit margins than DAWN in FY2025 (SNDX 96% to DAWN 90%)?
2. SNDX revenues come from 2 FDA approved therapies compared to DAWN's 1 FDA approved therapy (in theory lowering risk to an acquirer)?
3. SNDX 2 products both appear to have longer patent lives (Niktimvo FY36, Revuforj 6/8/37) than DAWN's Ojemda (June 35)?
We're only asking the question. This is not investment advice.
$INCY
$XBI
$IBB